Overall survival
Figure 2 · Panel A
Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Aurélie Montagne, Gildas Bertho, Thomas Papastergiou, Loïc Chartier, Romain Ricci, Fabrice Jardin, Hervé Ghesquières, Cédric Rossi, Franck Morschhauser, Corinne Haioun, Vincent Ribrag, Pierre Feugier, Gabriel Brisou, Lucie Oberic, Philippe Gaulard, Nicolas Giraud, Younès Bennani, Catherine Thieblemont, Véronique Baud
Blood Adv 10(2) 358-366
Early detection of ultrahigh-risk diffuse large B-cell lymphoma (DLBCL) is an unmet medical need to aid patient stratification for alternative treatment approaches. Metabolomics applied to biofluids of patients with cancer has emerged as a novel omics that could provide important information to better stratify these patients. In this work, the authors performed a retrospective study by nuclear magnetic resonance (NMR)-based metabolomics using plasma samples at diagnosis from 154 randomized patients with DLBCL treated by R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) (from the phase 3 REMARC [Reduced-intensity Maintenance therapy with Rituximab After R-CHOP in elderly patients with DLBCL] trial). Remarkably, a combination of 3 circulating metabolites was linked to lipid metabolism (named the "NMR score") that significantly affected overall survival (OS) (P< .0001) and progression-free survival (PFS) (P = .0003). The optimal cutoff for each metabolite was determined using X-Tile and confirmed by a training validation method. Combining 2-amino-butyrate, 3-hydroxy-butyrate, and LDL-1 lipoprotein yielded 3 risk groups with low- (0-1), intermediate- (2-3), and high-risk (4-5) patients. Germinal center B-cell (GCB)/non-GCB profile along with Bcl2 and Myc expression did not correlate with NMR score survival. In conclusion, the combination of 3 circulating metabolites linked to lipid metabolism is revealed as a feature that captures heterogeneity among patients with DLBCL. This NMR score seemed promising for DLBCL risk stratification, even among responder patients after R-CHOP treatment. This trial was registered at www.ClinicalTrials.gov as #NCT01122472.
2 个 Figure · 8 个 KM 面板
Figure 2. OS and PFS according to the metabolomics-based NMR score. (A) OS and (B) PFS for all randomized patients with DLBCL, n = 154. Class risks: low (0-1), intermediate (2-3), and high (4-5).
Figure 3. OS and PFS according to IPI, NCCN IPI, and aaIPI, for all randomized patients, n = 154. (A) OS and (B) PFS. Class risks: low: IPI = 0 to 2; intermediate: IPI = 3; and high: IPI = 4-5. (C) OS and (D) PFS. NCCN-IPI class risks: low-intermediate, high-intermediate, and high. (E) OS and (F) PFS. Class risks: low-low intermediate: aaIPI = 0 to 1, high intermediate-high: aaIPI = 2 to 3.
Figure 3 · Panel A
Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel B
Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel C
Panel C 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel D
Panel D 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel E
Panel E 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel F
Panel F 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。